Phaseline

Targets › CYP51A1

CYP51A1 (Lanosterol 14-alpha demethylase): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 4 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Infectious disease, Oncology, Immunology; next expected readout Mar 2027.

Sterol 14alpha-demethylase that plays a critical role in the cholesterol biosynthesis pathway, being cholesterol the major sterol component in mammalian membranes as well as a precursor for bile acid and steroid hormone synthesis. Cytochrome P450 monooxygenase that catalyzes the three-step oxidative removal of the 14alpha-methyl group (C-32) of sterols such as lanosterol (lanosta-8,24-dien-3beta-ol) and…. (UniProt, Q16850)

Open in Phaseline: the race on CYP51A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Weill Medical College of Cornell UniversityFluconazole
Cytochrome P450 51 inhibitor
CYP51A1Phase 3Crohn's DiseaseDec 2028
Merck & Co. (MSD)Posaconazole (MK-5592)
Cytochrome P450 51 inhibitor
CYP51A1Phase 2Invasive Fungal Infection; Posaconazole; Breast Cancer; Hematologic MalignancyMar 2027
David BoulwareOteseconazole
Azole metalloenzyme inhibitor targeting fungal sterol 14α demethylase (CYP51)
CYP51A1Phase 2HivApr 2032
University of California, DavisKetoconazole
Cytochrome P450 51 inhibitor
CYP51A1Phase 1Healthy–

Conditions

Invasive Fungal Infection (1) Posaconazole (1) Breast Cancer (1) Hematologic Malignancy (1) Crohn's Disease (1) Healthy (1) Hiv (1)

Modalities

small molecule (3), mixed (1)

Companies

Merck & Co. (MSD) (1) Weill Medical College of Cornell University (1) University of California, Davis (1) David Boulware (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.